Inventor · disambiguated record
Mark J. Cantwell
Also filed as: CANTWELL MARK · CANTWELL MARK J
13 granted patents·7 pending applications·120 citations·filing 1997–2022
90Inventor score
Top patents by PatentIndex Score
20 records- 0195US7928213B2Nucleic acids encoding chimeric CD154 polypeptidesUNIV CALIFORNIA·Filed 2009·Granted Apr 19, 2011·35 cites·17 claims
- 0293US7495090B2Nucleic acids encoding chimeric CD154 polypeptidesUNIV CALIFORNIA·Filed 2002·Granted Feb 24, 2009·45 cites·17 claims
- 0389US7786282B2Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domainUNIV CALIFORNIA·Filed 2001·Granted Aug 31, 2010·17 cites·24 claims
- 0481US7524944B2Chimeric nucleic acids encoding polypeptides comprising CD154 and TNF-αUNIV CALIFORNIA·Filed 2004·Granted Apr 28, 2009·6 cites·9 claims
- 0576US7906638B2Chimeric nucleic acids encoding polypeptides comprising CD70 and Fas ligand domainsUNIV CALIFORNIA·Filed 2009·Granted Mar 15, 2011·1 cites·24 claims
- 0674US8138310B2Chimeric CD154 polypeptidesPRUSSAK CHARLES E·Filed 2011·Granted Mar 20, 2012·2 cites·2 claims
- 0771US7964712B2Chimeric nucleic acids encoding polypeptides comprising TNF alpha, CD70 and FAS ligand domainsUNIV CALIFORNIA·Filed 2010·Granted Jun 21, 2011·1 cites·26 claims
- 0866US7070771B1Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cellsUNIV CALIFORNIA·Filed 1997·Granted Jul 4, 2006·13 cites·15 claims
- 0959US11594135B2Methods of CD40 activation and immune checkpoint blockadeUNIV TEXAS·Filed 2016·Granted Feb 28, 2023·0 cites·12 claims
- 1055US2023270784A1Oncolytic virus boosts t cell response for effective til therapyMEMGEN INC·Filed 2022·Application pending·0 cites
- 1154US2022090134A1Enhancing Immunity Using Chimeric CD40 Ligand and Coronavirus VaccineMEMGEN INC·Filed 2021·Application pending·0 cites
- 1250US12239666B2Oncolytic virus or antigen presenting cell mediated cancer therapy using type I interferon and CD40-ligandH LEE MOFFITT CANCER CT & RES·Filed 2019·Granted Mar 4, 2025·0 cites·8 claims
- 1345US12171803B2Methods of CD40 and toll like receptor immune activationMEMGEN INC·Filed 2018·Granted Dec 24, 2024·0 cites·10 claims
- 1445US11951141B2Replication-enhanced oncolytic adenovirusesMEMGEN INC·Filed 2020·Granted Apr 9, 2024·0 cites·7 claims
- 1545US2012116052A1Nucleic Acid Molecules Encoding TNF-Alpha Ligand Polypeptides Having a CD154 DomainPRUSSAK CHARLES E·Filed 2011·Application pending·0 cites
- 1643US2009221594A1Stable pharmaceutical compositions of 5, 10 methylenetrahydrofolateCHEN ANDREW X·Filed 2006·Application pending·0 cites
- 1739US11298420B2Armed oncolytic virusesMEMGEN LLC·Filed 2017·Granted Apr 12, 2022·0 cites·43 claims
- 1838US2007280944A1Use of 5,10-Methylene Tetrahydrofolate for the Treatment of CancerADVENTRX PHARMACEUTICALS INC·Filed 2005·Application pending·0 cites
- 1933US2018244750A1Methods for treatment of cancerMEMGEN LLC·Filed 2016·Application pending·0 cites
- 2032US2018169271A1Armed replication-competent oncolytic adenovirusesMEMGEN LLC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark J. Cantwell files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →